Empagliflozin Fails to Reduce Events After Acute MI
Empagliflozin, an SGLT2 inhibitor, did not significantly reduce first heart failure hospitalization…
E-Cigarette Use Linked To High Risk Of Heart Failure: Study
Vaping is often seen as a safer alternative to smoking, but recent…
Sun Pharma Industries Gets CDSCO Panel Nod To Manufacture Market Elagolix Tablets 150 mg,200 mg
Sun Pharma Industries has received approval from the Central Drugs Standard Control…
Smarter Aging: The Importance of Health Tech Planning
Health Tech Planning is crucial for supporting healthy aging by integrating technology…
What General Practice wants from the IMO
The Irish Medical Organisation (IMO) is essential for the health system in…
Zero Overdose, Pear Suite join forces to curb opioid epidemic
Nonprofit organization Zero Overdose has partnered with Pear Suite to provide training…
More Kids Are Dying of Drug Overdoses. Could Pediatricians Do More to Help?
A 17-year-old boy named Sam is being treated for an addiction to…
Empagliflozin did not cut risk for death, HF hospitalization after heart attack: EMPACT-MI
The EMPACT-MI trial investigated the effects of empagliflozin treatment soon after an…
Teladoc CEO Jason Gorevic to leave the company immediately
Teladoc Health CEO Jason Gorevic unexpectedly departs, replaced by CFO Mala Murthy.…
Junior doctors’ strike in South Korea: systemic barriers undermine medical practice
Hyunmi Park, an associate professor at Korea University College of Medicine, discusses…